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Abstract
Background: Sentinel lymph node (SLN) biopsy is the standard of care for the surgical assessment
of the axilla during breast cancer surgery. However, the diagnostic accuracy of intraoperative
frozen section analysis for confirming metastatic involvement of SLNs in cases of invasive lobular
carcinoma (ILC) versus that of invasive ductal carcinoma (IDC) has generated controversy
secondary to a frequently low-grade cytologic appearance and an often discohesive pattern
displayed by metastatic lymph nodes in ILC. In the current report, we present a comparison of
intraoperative frozen section analysis for confirming the presence of metastatic disease within SLNs
during breast cancer surgery for ILC and IDC.
Methods: We evaluated the results of 131 consecutive cases of ILC from 1997 to 2008 and 133
cases of IDC (selected by a random sequence generator program) from amongst 1163 consecutive
cases of IDC from the same time period. All cases had at least one SLN that had both intraoperative
frozen section analysis and confirmatory permanent section analysis performed.
Results: No statistically significant difference was found in the sensitivity (67% vs. 75%, P = 0.385),
specificity (100% vs. 100%), accuracy (86% vs. 92%, P = 0.172), false negative rate (33% vs. 25%, P
= 0.385), negative predictive value (81% vs. 89%, P = 0.158), and positive predictive value (100% vs.
100%) for frozen section analysis for confirming the presence of metastatic disease within SLNs
during breast cancer surgery for ILC and IDC.
Conclusion: Since there was no statistically significant difference in sensitivity, specificity,
accuracy, false negative rate, negative predictive value, and positive predictive value between frozen
section analysis of SLNs for patients with ILC and IDC, the clinical accuracy of confirming
metastatic involvement of SLNs on frozen section analysis for ILC should not be considered
inferior to the clinical accuracy for IDC. Therefore, frozen section analysis of all SLNs during breast
cancer surgery in patients with ILC should remain the standard of care in order to reduce the risk
of the need of a later, separate axillary lymph node dissection.
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Sentinel lymph node (SLN) biopsy with intraoperative
frozen section analysis has become a standard of care in
the surgical staging of the axilla during breast cancer sur-
gery [1-3]. The sensitivity of intraoperative frozen section
analysis for identifying nodal metastases within SLNs dur-
ing breast cancer surgery has been reported to vary widely
from the range of 44% to 95% [4-17], with most series
reporting the sensitivity of frozen section analysis in the
range of 60% to 75% [5,7-9,11-13,15-17].
The difficulty with identifying nodal metastases from
invasive lobular carcinoma (ILC) versus invasive ductal
carcinoma (IDC) has long been debated within the
pathology and surgical communities [17-24]. It has been
suggested that individual tumor cells involving the sub-
capsular sinuses of SLNs in patients with ILC can closely
resemble benign lymphocytes and histiocytes when eval-
uated at frozen section [17,20-24]. Likewise, it has been
suggested that the bland cytologic features, round to spin-
dled shape, and discohesive proliferation of ILC cells can
make their diagnosis on H&E alone especially difficult
[17,20-22,24]. Due to this perceived difficulty in identify-
ing metastatic disease within lymph nodes harvested from
patients with ILC, it has been suggested by several authors
that false negative frozen section results are more likely in
SLN biopsy for ILC as compared to IDC [12,13,17].
The rate of nodal positivity of ILC versus IDC has been
extensively compared in the literature [25-36], with most
studies showing no significant difference [25,28,30-
33,35,36], and only isolated reports showing a significant
difference in nodal positivity favoring more in ILC [26]
and favoring more in IDC [27,29,34]. Since the diagnostic
accuracy of intraoperative frozen section analysis for con-
firming the presence of metastatic disease within SLNs for
ILC versus IDC has long been contended, in the current
report, we present a comparison of intraoperative frozen
section analysis for confirming the presence of metastatic




This study was performed under an established Pathology
Department protocol approved by Institutional Review
Board for the prospectively maintained CoPath database
of the Department of Pathology at The Ohio State Univer-
sity.
All female cases of ILC that had undergone frozen section
analysis and confirmatory permanent section analysis
that was performed on at least one SLN candidate during
definitive breast cancer surgery between the time period of
1997 to 2008 were identified from within the CoPath
database. This included 131 cases of ILC. From the same
time period of 1997 to 2008, all female cases of IDC (n =
1163) that had undergone intraoperative frozen section
analysis and confirmatory permanent section analyses
that was performed on at least one SLN during definitive
breast cancer surgery were also identified from within the
CoPath database. Using an internet-available random
sequence generator program called "RANDOM.ORG"
[37], a similar number of IDC cases (n = 133) were ran-
domly selected from amongst the entire group of IDC
cases in order to generate a cohort of IDC cases to be used
for direct comparison to the ILC cases.
All female breast cancer cases identified from within the
CoPath database that reported mixed lobular/ductal fea-
tures were excluded from consideration for inclusion in
either the ILC group or the IDC group.
Surgical considerations
The technical details with regards to performing SLN
biopsy during breast cancer surgery at The Ohio State Uni-
versity, including the exact methods of injection of radio-
colloid and vital blue dye, have been previously described
for the time period prior to 2001 [38] and for the time
period since 2001 [39].
Histopathology considerations
At the current time, during intraoperative consultation for
frozen section analysis at The Ohio State University, each
SLN is grossly sectioned at 0.2 cm interval portions. The
most superficial 25% of the thickness of each resulting 0.2
cm SLN tissue section is processed for frozen section anal-
ysis, providing at least three separate levels of tissue for
frozen section analysis. These frozen sections are then
hand-stained by routine Hematoxylin and Eosin (H&E)
staining. The remaining tissue of each resulting 0.2 cm
SLN tissue section, encompassing 75% of the thickness of
that tissue, is then sent for routine processing. Three sepa-
rate levels (level 1, 2, and 3) on permanent slides are then
sectioned at approximately 500 μm intervals and levels 1
and 3 are stained with H&E by an automated staining
device, while level 2 is immunohistochemically stained
with cytokeratin AE1/AE3. In those specific cases that are
reported as having a SLN that is positive for metastatic car-
cinoma on the frozen section analysis, the level 2 section
from each submitted SLN is omitted from undergoing
routine cytokeratin AE1/AE3 immunohistochemistry
(IHC). We do recognize that the exact methodology of
performing frozen section analysis and permanent his-
topathologic analysis of SLNs for breast cancer cases has
changed during the study period from 1997 to 2008.
Metastatic disease within a sentinel lymph node was
defined as "macrometastatic" if any given tumor deposit
was greater than 2.0 mm and was defined as "micrometa-Page 2 of 8
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2.0 mm. Due to the fact that the study period extends back
to 1997 and due to the fact that there was some degree of
variability in the reporting style of the multiple original
reading pathologists for each of these cases, it was not fea-
sible to accurately further subclassify micrometastatic dis-
ease into "micrometastatic" and "submicrometastatic"
subclassifications.
It is important to note that the inception of the perform-
ance of routine cytokeratin AE1/AE3 IHC for breast cancer
cases in which all of the SLNs were reported as negative at
the time of the initial frozen section analysis was initiated
at The Ohio State University in May 2006. Before May
2006, it was specifically at the discretion of the reading
pathologist as to whether or not to utilize cytokeratin
AE1/AE3 IHC for further and for more in-depth evalua-
tion of SLNs in any given breast cancer case. Therefore,
since it would be difficult to assess the impact of cytoker-
atin AE1/AE3 IHC on the overall results reported in the
current study secondary to the obvious heterogeneity of
the application of cytokeratin AE1/AE3 IHC from 1997
through 2006, no attempt was made to differentiate the
results of permanent pathologic evaluation based upon
whether cytokeratin AE1/AE3 IHC was used or not used.
Data collection and analyses
Multiple patient variables, primary tumor variables, and
SLN variables were evaluated for each case. Data collec-
tion of all those variables was simply accomplished by
way of retrospective review of the electronic pathology
report posted by the original reading pathologist for each
case. A re-review of the actual H&E frozen section slides,
H&E permanent section slides, and cytokeratin IHC slides
for these cases was not undertaken as part of the current
analysis. If a given variable was absent from the electronic
pathology report posted by the original reading patholo-
gist, that variable was recorded as unknown for that par-
ticular case.
The number of true positive (TP), true negative (TN), false
negative (FN), and false positive (FP) were determined for
frozen section analysis compared to permanent section
analysis for the finding of positive SLN for ILC versus IDC.
Then, for both ILC and IDC, the sensitivity (TP/(TP+FN)),
specificity (TN/(TN+FP)), accuracy ((TP+TN)/total
patients), false negative rate (FN/(TP+FN)), negative pre-
dictive value (TN/(TN+FN)), and positive predictive value
(TP/(TP+FP)) were calculated. All these variables were
determined on a per patient basis and were not deter-
mined on a per SLN basis.
The software program SPSS 16.0 for Windows (SPSS, Inc.,
Chicago, Illinois) was used for all statistical analyses. For
univariate comparisons of categorical variables, either
Pearson chi-square test or Fisher exact test was utilized.
Continuous variables were expressed as median (range).
For univariate comparisons of continuous variables, one-
way analysis of variance (ANOVA) was utilized. All
reported univariate P-values were two-sided. All univari-
ate P-values determined to be 0.05 or less were considered
to be statistically significant.
Results
Patient and tumor demographics for ILC and IDC patients
are shown in Table 1. ILC patients tended to be older. ILC
patients generally had larger tumors and more often dis-
played multifocal and multicentric disease. ILC generally
had a lower histologic tumor grade and were more often
estrogen receptor positive, progesterone receptor positive,
and Her-2/neu negative. ILC less often had displayed lym-
phovascular invasion.
The SLN demographics, including frozen section analysis
results, permanent section analysis results, the size of the
SLN metastasis, and the classification into macrometa-
static disease and micrometastatic disease for ILC and IDC
patients are shown in Table 2. No statistically significant
difference was noted in any of these SLN demographics
variables for ILC versus IDC patients.
The number of TP, TN, FN, and FP were determined for
frozen section analysis compared to permanent section
analysis for the finding of a positive SLN for ILC versus
IDC patients and are shown in Table 3. The nature of the
classification of metastatic disease (i.e., macrometastatic
versus micrometastatic) amongst false negative cases for
patients with a positive sentinel lymph node for ILC ver-
sus IDC is shown in Table 4. No statistically significant
difference was noted in any of these variables for ILC ver-
sus IDC patients.
The sensitivity, specificity, accuracy, false negative rate,
negative predictive value, and positive predictive value of
frozen section analysis compared to permanent section
analysis for the finding of positive SLN for ILC versus IDC
patients were calculated and are shown in Table 5. No sta-
tistically significant difference was noted in any of these
variables for ILC versus IDC patients.
Discussion
The primary reason for undertaking this current analysis
was the fact that it has been the longstanding general
opinion of many surgical pathologists within the pathol-
ogy community, including our own, that SLNs in ILC
cases are notoriously more difficult to interpret, especially
at the time of frozen section analysis. This longstanding
contention has been eloquently addressed and debated
within the literature [18-24]. Best articulated by Creager et
al [21], although not necessarily agreed upon by theirPage 3 of 8
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that the intraoperative detection of ILC can be highly
problematic secondary to its low-grade cytomorphology
and its tendency to infiltrate metastatic sites in a single cell
pattern. This assertion that was articulated by Creager et al
[21] suggests that such architectural and cytomorphologic
features of ILC within a given metastatic lymph node can
result in occasionally missing even relatively large nodal
metastases on intraoperative frozen section evaluation
that are then only discovered, much to the surprise of the
pathologist and surgeon, on permanent H&E sections
and/or cytokeratin AE1/AE3 IHC stained sections. In this
regard, our goal was to compare the diagnostic accuracy of
intraoperative frozen section analysis for confirming the
presence of metastatic disease within SLNs during breast
cancer surgery for ILC and IDC, in order to confirm or dis-
pel the above, longstanding contention.
In our study, the sensitivity of frozen section analysis
(67% for ILC patients, 75% for IDC patients, and 70% for
all patients) was well within the range of sensitivity for
frozen section analysis results (i.e. 60% to 75% range) in
most previously reported series in the literature for SLN
biopsy during breast cancer surgery [5,7-9,11-13,15-17].
Therefore, our frozen section analysis results, based on
sensitivity, are highly consistent with the mainstream
practice of intraoperative frozen section analysis for SLN
biopsy during breast cancer surgery.
Table 1: Patient and tumor demographics for invasive lobular carcinomas and invasive ductal carcinomas
ILC (n = 131) IDC (n = 133) Total cases (n = 264) P-value
Age (years) 59 (35–87) 55 (24–82) 57 (24–87) 0.001
Tumor size (cm) 2.0 (0.2–9.0) 1.5 (0.1–6.5) 1.7 (0.1–9.0) 0.006
T-stage
T1 75(58%) 88 (66%) 163 (62%) 0.298
T2 49 (38%) 43 (32%) 92 (35%)
T3 5 (4%) 2 (2%) 7 (3%)
T4 1 (1%) 0 (0%) 1 (0.5%)
Tumor focality
Unifocal 97 (75%) 123 (93%) 220 (84%) <0.001
Multifocal 19 (15%) 9 (7%) 28 (11%)
Multicentric 14 (11%) 1 (1%) 15 (6%)
Histologic grade
Grade 1 40 (31%) 32 (24%) 72 (27%) <0.001
Grade 2 57 (44%) 52 (39%) 109 (41%)
Grade 3 17 (13%) 48 (36%) 65 (25%)
Unknown 17 (13%) 1 (1%) 18 (7%)
ER status
Positive 121 (93%) 96 (72%) 217 (82) <0.001
Negative 2 (2%) 29 (22%) 31 (12%)
Unknown 8 (6%) 8 (6%) 16 (6%)
PR status
Positive 108 (82%) 81 (61%) 189 (72%) <0.001
Negative 16 (12%) 44 (33%) 60 (23%)
Unknown 7 (5%) 8 (6%) 15 (6%)
Her-2/neu
Positive 13 (10%) 35 (26%) 48 (18%) 0.003
Negative 106 (81%) 87 (65%) 193 (73%)
Unknown 12 (9%) 11 (8%) 23 (9%)
LVI
Positive 20 (15%) 41 (31%) 61 (23%) 0.005
Negative 109 (83%) 92 (69%) 201 (76%)
Unknown 2 (2%) 0 (0%) 2 (1%)
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; LVI, lymphovascular invasionPage 4 of 8
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nificant difference in the false negative rate for frozen sec-
tion analysis for SLN biopsy for ILC as compared to IDC
(33% for ILC, 25% for IDC, P = 0.385). Although this may
initially seem surprising to some, the vast majority of the
literature supports the routine use of intraoperative frozen
section analysis for SLN biopsy during breast cancer sur-
gery for ILC cases [10,12,13,16,21,24,40,41]. Neverthe-
less, several authors have previously reported that false
negative frozen section results are more likely in SLN
biopsy for ILC as compared to for IDC [12,13,17].
Leidenius et al [12] analyzed a total of 375 breast cancers
and reported that the false-negative rate for frozen section
analysis during SLN biopsy was more common for ILC
than IDC (28% versus 8%, P < 0.01) in an overall analysis
of 102 ILC versus 194 IDC. In our estimation, the distri-
bution of tumor types (i.e., ILC versus IDC) reported by
Leidenius et al [12] is very perplexing. In their series [12],
they reported seeing 102 cases of ILC among a total of 375
total breast cancer cases during a 22 month time period
from 01/02/2001 to 11/7/2002 in Helsinki, Finland. This
signifies that ILC makes up an astonishing 27.2% of all
the breast cancers seen in Helsinki, Finland. This is in
stark contrast to the maximum of 10% to 15% of ILC cases
that are generally seen among all presenting breast cancers
within the United States [17,26,34,35] and worldwide
[27,30,31,33,36,41,42]. Secondly, they found an unusu-
ally low false negative rate of frozen section analysis for
SLNs for IDC cases (8%) as compared to for ILC cases
(28%) [12]. In contrast, most series in the literature gen-
erally report a false negative rate of frozen section analysis
for SLN biopsy for breast cancer cases is in the range of
anywhere from 26% to 56% [5,7,8,10,11,13-15,17],
including our own current series in which the false nega-
tive rate of frozen section analysis for SLN biopsy was
33% for ILC, 25% for IDC, and 30% for all breast cancer
cases. This particular aspect of Leidenius et al [12]
reported series can not be easily explained in view of the
rest of the reported literature and casts some doubt into
their results and contention that false negative frozen sec-
tion results are more likely in SLN biopsy for ILC as com-
pared to for IDC.
Similarly, Holck et al [13] analyzed a total of 265 breast
cancers and reported that false negative findings were
overrepresented for ILC on frozen section analysis during
SLN biopsy (i.e., 5 of 28 or 17.9% of the false negative fro-
zen section results were from ILC). Despite the fact that
Holck et al [13] made this statement, they failed to specify
within their paper exactly how many ILC cases they ana-
lyzed from among the 265 breast cancers they saw in Hil-
leroed, Denmark over a 20 month period of time from
February 2001 through September 2002 and did not pro-
vide enough raw data or P-values to verify their claim for
overrepresentation.
Table 2: The sentinel lymph node demographics for invasive lobular carcinomas and invasive ductal carcinomas
ILC IDC Total cases P-value
Frozen section analysis of SLN
Positive 36 (28%) 33 (25%) 69 (26%) 0.622
Negative 95 (73%) 100 (75%) 195 (74%)
Permanent section analysis of SLN
Positive 54 (41%) 44 (33%) 98 (37%) 0.171
Negative 77 (59%) 89 (67%) 166 (63%)
Size of SLN metastasis (mm) 6.0 (0.5–25.0) 5.0 (0.1–32.0) 5.5 (0.1–32.0) 0.808
Classification of metastatic disease
Macrometastatic (>2.0 mm) 36 (28%) 28 (21%) 64 (24%) 0.378
Micrometastatic (≤ 2.0 mm) 16 (12%) 12 (9%) 28 (11%)
Unknown classification 2 (1.5%) 4 (3%) 6 (2%)
No metastatic disease 77 (59%) 89 (67%) 166 (63%)
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; SLN, sentinel lymph node
Table 3: The number of TP, TN, FN, and FP for frozen section 
analysis compared to permanent section analysis for confirming 
the presence of metastatic disease within sentinel lymph node 
candidates for invasive lobular carcinomas and invasive ductal 
carcinomas
ILC IDC Total cases P-value
TP 36 33 69 0.622
TN 77 89 166 0.171
FN 18 11 29 0.155
FP 0 0 0 ------
Total 131 133 264
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; TP, 
true positive; TN, true negative; FP, false positive; FN, false negativePage 5 of 8
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5298 breast cancers and reported that the false negative
rate for frozen section analysis during SLN biopsy was
more common for ILC than IDC (47.6% versus 37.8%, P
= 0.006) in an overall analysis of 574 ILC versus 4531
IDC. Despite the statistically significant difference
between ILC and IDC that they reported, Chan et al [17]
went on to state in their discussion that "although this dif-
ference is statistically significant, it may not be clinically
significant, as frozen section successfully detected a
majority of SLN metastases in both groups". Likewise,
Chan et al [17] never concluded in their report that frozen
section analysis of SLNs during breast cancer surgery for
ILC should be abandoned.
Therefore, it is reasonable to conclude, based on our
results showing no significant statistical difference in the
false negative rate on frozen section analysis for SLNs in
ILC versus IDC cases, that intraoperative frozen section
analysis of SLNs during breast cancer surgery for ILC
should remain an important standard of care. This allows
for accurate intraoperative assessment of the nodal status
of the axilla, thus allowing the surgeon to appropriately
proceed with an immediate concomitant axillary lymph
node dissection based upon the intraoperative finding of
a positive SLN and thus minimizing the need for an addi-
tional, subsequent, delayed axillary procedure. Clearly,
intraoperative frozen section analysis during SLN biopsy
is no less important for ILC than it is for IDC.
Despite the fact that our results do not show any signifi-
cant difference in the diagnostic accuracy of intraoperative
frozen section analysis using hand-stained, routine H&E
staining for confirming the presence of metastatic disease
within SLN candidates during breast cancer surgery for
ILC and IDC, several relevant issues with regards to the
potential impact of IHC on the detection rate of axillary
lymph node metastases in cases of ILC seem to be worth
further discussion.
Recently, Tan et al [43] retrospectively analyzed a cohort
of 368 previously presumed node-negative breast cancer
patients (319 with IDC and 49 with ILC) that were treated
with axillary lymph node dissection between 1976 and
1978 and who had 20-year follow up. They retrospectively
performed IHC in order to attempt to identify occult axil-
lary lymph node metastases based upon IHC detection
versus historical standard H&E detection. From their ret-
rospective performance of IHC, they were able to identify
three very important pathological features that were spe-
cifically attributable to ILC cases. First, ILC cases had a
higher rate of conversion from node negative to node pos-
itive than did IDC cases (40% versus 20%). Second, ILC
cases had an over-representation IHC-detected disease
versus H&E-detected disease (36% versus 15%). Third,
ILC cases had an over-representation among patients with
single-cell metastases versus clustered metastases (59%
versus 7%). Certainly, these pathological features demon-
strate the potential impact that IHC may have on the over-
all diagnostic accuracy of confirming the presence of
metastatic disease within SLN candidates for ILC cases.
Nevertheless, since this study cohort [43] represents a
group of patients treated in the pre-SLN biopsy era, these
IHC results have no direct correlation to or bearing upon
the current intraoperative assessment of frozen section
analysis for confirming the presence of metastatic disease
within SLN candidates during breast cancer surgery for
ILC.
More relevant to the SLN biopsy era, Patil and Susnik [24]
recently retrospectively reviewed 76 patients with ILC
undergoing SLN biopsy during the time period of 2003 to
2007. Of the 76 cases, 24 cases (32%) were positive for
metastatic disease (21 macrometastatic and three
Table 4: The nature of the classification of metastatic disease amongst false negative cases for patients with a positive sentinel lymph 
node for invasive lobular carcinomas and invasive ductal carcinomas
False negative cases ILC IDC Total cases P-value
Macrometastatic (>2.0 mm) 5 (28%) 2 (18%) 7 (24%) 0.807
Micrometastatic (≤ 2.0 mm) 11 (61%) 8 (73%) 19 (66%)
Unknown classification 2 (11%) 1 (9%) 3 (10%)
Total 18 (100%) 11 (100%) 29 (100%)
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma
Table 5: The sensitivity, specificity, accuracy, false negative rate, 
negative predictive value, and positive predictive value of frozen 
section analysis compared to permanent section analysis for the 
finding of a positive sentinel lymph node for invasive lobular 
carcinomas and invasive ductal carcinomas
ILC IDC Total cases P-value
Sensitivity 67% 75% 70% 0.385
Specificity 100% 100% 100% ------
Accuracy 86% 92% 89% 0.172
False negative rate 33% 25% 30% 0.385
Negative predictive value 81% 89% 85% 0.158
Positive predictive value 100% 100% 100% ------
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinomaPage 6 of 8
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lated tumor cells (submicrometastatic) on IHC only. All
macrometastatic cases (n = 21) and two of three
micrometastatic cases were identified on standard H&E
evaluation alone. All cases of isolated tumor cells (n = 14)
and one micrometastatic case were detected on IHC
alone. Therefore, based on IHC, they officially changed
the axillary lymph node status from negative to positive in
only one case of micrometastatic disease. They concluded
that upstaging very rarely occurred with the use of IHC
[24]. Likewise, they concluded that yielding a diagnosis of
isolated tumor cells, which prognostically is not com-
pletely understood at this time, rarely results in any devi-
ation of the treatment plan and provides no additional
advantage over that of a thorough standard H&E evalua-
tion [24].
A last relevant point of discussion with regards to IHC is
that several groups have advocated the specific use of
rapid intraoperative IHC in addition to frozen section
H&E stained levels and possibly touch imprints cytology.
Leikola et al [23] analyzed 995 breast cancer patients (523
with IDC and 245 with ILC) undergoing SLN biopsy dur-
ing the time period of 2001 to 2007. They demonstrated
that rapid intraoperative IHC on frozen sections analysis
improved the sensitivity of detecting metastatic disease
within SLNs from 66% (without IHC) to 87% (with IHC)
for patients with ILC (P = 0.02). Similarly, Weinberg et al
[22] analyzed 59 breast cancer patients with ILC using
rapid intraoperative IHC on touch imprint cytology. They
demonstrated that their sensitivity for identifying a SLN
containing metastatic disease was increased from 41.9%
(without IHC) to 54.8% (with IHC) using rapid intraop-
erative IHC on touch imprint cytology and concluded that
rapid intraoperative IHC on touch imprint cytology
enhances the intraoperative diagnosis of SLN metastases
in patients with ILC. However, no specific P-values were
reported by Weinberg et al [22] to support their data or
their conclusions.
While IHC is currently widely utilized at many institu-
tions around the globe as part of standard histopathologic
evaluation of SLNs for breast cancer, the specific relevance
and impact of IHC can not be directly addressed within
the context of the findings of our current report, since we
did not specifically analyze IHC findings as an independ-
ent variable within our overall assessment of the diagnos-
tic accuracy of intraoperative frozen section analysis for
confirming the presence of metastatic disease within SLNs
candidates during breast cancer surgery for ILC and IDC.
Obviously, the specific impact of IHC on the overall
assessment of the diagnostic accuracy of intraoperative
frozen section analysis for confirming the presence of
metastatic disease is multifactorial and is beyond the
scope of our current discussion.
Conclusion
Since there was no statistically significant difference in
sensitivity, specificity, accuracy, false negative rate, nega-
tive predictive value, and positive predictive value
between frozen section analysis of SLNs for patients with
ILC and IDC, the clinical accuracy of confirming meta-
static involvement of SLNs on frozen section analysis for
ILC should not be considered inferior to the clinical accu-
racy for IDC. Therefore, frozen section analysis of all SLNs
during breast cancer surgery in patients with ILC should
remain the standard of care in order to reduce the risk of
the need of a later, separate axillary lymph node dissec-
tion.
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